Michael U Callaghan

9PUBLICATIONS
20CO-AUTHORS
Immunogenetics (incl. genetic immunology)Epidemiological methodsMajor global burdens of diseaseHaematologyCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 28, 2021
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.

Christine Kempton, Peter Trask, Aric Parnes

|Sep 24, 2020
Bortezomib treatment of steroid-refractory Evans syndrome in children.

Serina B Beydoun, Yogindra Persaud, Jennifer Lafferty

|Apr 25, 2019
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan

|Nov 15, 2018
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Johannes Oldenburg, Johnny N Mahlangu, Willem Bujan

|Oct 09, 2018
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.

Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan

|May 18, 2018
Novel therapeutics for hemophilia and other bleeding disorders.

Michael U Callaghan, Robert Sidonio, Steven W Pipe

Pageof 2

Frequent Collaborators

4 joint publications

Johnny N Mahlangu

3 joint publications

Rebecca Kruse-Jarres

2 joint publications

Johannes Oldenburg

2 joint publications

Sylvia von Mackensen